BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 2147887)

  • 1. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings.
    Jung-Hoffmann C; Kuhl H
    Contraception; 1990 Oct; 42(4):423-38. PubMed ID: 2147887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J; Müller U; Düsterberg B
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 150 micrograms desogestrel.
    Kuhl H; Jung-Hoffmann C; Heidt F
    Contraception; 1988 Sep; 38(3):381-90. PubMed ID: 2971509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.
    Back DJ; Houlgrave R; Tjia JF; Ward S; Orme ML
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):219-25. PubMed ID: 2004043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives.
    Jung-Hoffmann C; Kuhl H
    Contraception; 1989 Sep; 40(3):299-312. PubMed ID: 2527727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
    Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III clinical trial with a new oral contraceptive containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol.
    Lammers P; op ten Berg M
    Acta Obstet Gynecol Scand; 1991; 70(6):497-500. PubMed ID: 1837199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene.
    Kuhl H; Jung-Hoffmann C; Heidt F
    Contraception; 1988 Oct; 38(4):477-86. PubMed ID: 3208516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
    Dibbelt L; Knuppen R; Jütting G; Heimann S; Klipping CO; Parikka-Olexik H
    Contraception; 1991 Jan; 43(1):1-21. PubMed ID: 1825969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene.
    Zichella L; Sbrignadello C; Tomassini A; Di Lieto A; Montoneri C; Zarbo G; Mancone M; Pietrobattista P; Bertoli G; Perrone G
    Adv Contracept; 1999; 15(3):191-200. PubMed ID: 11019950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
    Bergink W; Assendorp R; Kloosterboer L; van Lier W; Voortman G; Qvist I
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2132-7. PubMed ID: 2147817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism.
    Jung-Hoffman C; Kuhl H
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2183-97. PubMed ID: 2147819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.